论文部分内容阅读
目的:探讨布地奈德雾化吸入治疗急性会厌炎的临床疗效。方法:将54例急性会厌炎患者随机分为观察组(26例)和对照组(28例)。所有患者均给予抗生素、激素、吸氧、补充水电解质等常规综合治疗。观察组在常规治疗的基础上给予布地奈德治疗。两组连续治疗7 d后进行疗效比较。结果:观察组25例中治愈14例,治愈率为53.8%;对照组28例中治愈15例,治愈率为53.6%。两组治愈率比较,差异无统计学意义(P>0.05)。观察组不良反应发生率为30.8%,对照组为60.7%。两组不良反应发生率相比,差异有统计学意义(χ2=4.86,P<0.05)。结论:布地奈德雾化吸入辅助治疗急性会厌炎全身副作用小,临床疗效满意,可于临床推广应用。
Objective: To investigate the clinical efficacy of inhaled budesonide in the treatment of acute epiglottitis. Methods: 54 patients with acute epiglottitis were randomly divided into observation group (26 cases) and control group (28 cases). All patients were given antibiotics, hormones, oxygen, supplemented with water and electrolyte and other conventional comprehensive treatment. The observation group was treated with budesonide on the basis of routine treatment. Two groups of continuous treatment for 7 days after the comparison of efficacy. Results: In the observation group of 25 cases, 14 cases were cured and the cure rate was 53.8%. In the control group, 15 cases were cured and the cure rate was 53.6%. There was no significant difference between the two groups in the cure rate (P> 0.05). The incidence of adverse reactions in the observation group was 30.8% and in the control group 60.7%. There was significant difference between the two groups in incidence of adverse reactions (χ2 = 4.86, P <0.05). Conclusion: Budesonide inhalation adjuvant treatment of acute epiglottitis systemic side effects, clinical efficacy satisfactory, can be clinically applied.